Breaking News

CEL-SCI Developing Immunotherapy to Treat Coronavirus

Will leverage LEAPS peptide technology to reduce COVID-19 viral load and tissue damage resulting from infection in the lungs.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

CEL-SCI Corp. is developing an immunotherapy with the potential to treat coronavirus using its LEAPS peptide technology. The LEAPS peptides will utilize conserved regions of coronavirus proteins to stimulate protective cell mediated T cell responses and reduce viral load.  The LEAPS peptide technology can be used to construct immunotherapeutic peptides that exhibit both antiviral and anti-inflammatory properties. These products target the virus infection as well as elicit the appropriate protect...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters